Nutrition, lifestyle, physical activity, and supportive care during chemotherapeutic treatment;Ernährung, lebensweise, aktivitäten und supportive maßnahmen unter chemotherapeutischer behandlung

Urologe - Ausgabe A

Volumn 45, Issue 5, 2006, Pages 555-566

  Lummen G ^a   Jager T ^b   Sommer, F ^c   Ebert, T ^d   Schmitz Draeger, B ^d  

^a St Agnes Hospital Bocholt gGmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d EuromedClinic   (Germany)

Author keywords

Antioxidants; Chemotherapy; Lifestyle; Nutrition; Supportive care

Indexed keywords

ALPHA TOCOPHEROL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CEPHALOSPORIN; CISPLATIN; DEXAMETHASONE; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOMEPROMAZINE; LORAZEPAM; METOCLOPRAMIDE; PIPERACILLIN; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TAZOBACTAM; VANCOMYCIN; VINCRISTINE; VITAMIN D;

ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY; COMORBIDITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; LIFESTYLE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUTRITION; OSTEOPOROSIS; PHYSICAL ACTIVITY; SMOKING CESSATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; VOMITING;

DRUG THERAPY; HUMANS; LIFE STYLE; MOTOR ACTIVITY; NEOPLASMS; NURSING CARE; NUTRITIONAL STATUS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 33646889104     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1037-3     Document Type: Article

References (114)

1. Adamson JW, Ludwig H (1999) Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin α) in the treatment of the anemia of cancer. Oncology 56: 46-53
2. Alley E, Green R, Schuchter L (2002) Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14(2): 212-216
3. American Cancer Society (2001) Nutritional advice for cancer survivors. CA Cancer J Clin 51: 151-152
4. Aveyard P, Adab P, Cheng KK et al. (2002) Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 90: 228-239
5. Baker J, McCune JS, Harvey RD et al. (2000) Granulocyte colony-stimulating factor use in cancer patients. Ann Pharmacother 34: 851-857
6. Bauer JD, Capra S (2005) Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy - a pilot study. Support Care Cancer: 13(4): 270-274
7. Berglund G, Bolund C, Gustavsson UL, Sjoden PO (1993) Starting again - a comparison study of a group rehabilitation program for cancer patients. Acta Oncol 32(1): 15-21
8. Birch R, Weaver CH, Carson K, Buckner CD (1998) A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin. Bone Marrow Transplant 22(7): 685-688
9. Boehm DK (1996) Paclitaxel premedication regimens. J Natl Cancer Inst 88: 463-465
10. Bokemeyer C, Oechsle K, Hartmann JT et al. (2002) Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87(10): 1066-1071
11. Bravata DM, Sanders L, Huang J et al. (2003) Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 289: 1837-1850
12. Breitkreutz R, Tesdal K, Jentschura D et al. (2005) Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr 117(19-20): 685-92
13. Brennan P, Bogillot O, Cordier S et al. (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86: 289-294
14. Brock N (1989) Oxazaphosphorine cytostatics: post - present - future. Cancer Res 49: 1-7
15. Bruns F, Micke O, Bremer M (2003) Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 1(2): 121-130
16. Caffrey PB, Frenkel GD (2000) Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 46(1): 74-78
17. Cao S, Durrani FA, Rustum YM (2004) Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10(7): 2561-2569
18. Cellarier E, Durando X, Vasson MP et al. (2003) Methionine dependency and cancer treatment. Cancer Treat Rev 29(6): 489-499
19. Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20(4): 1128-1143
20. Ciernik IF, Schnaz U, Gmür J (1999) Delaying treatment with granulocyte colony-stimulating factor after allogenic bone marrow transplantation for haematological malignancies: a prospective randomized trial. Bone Marrow Transplant 24: 147-151
21. Cohen JH, Kristal AR, Stanford JL. (2000) Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92: 61-68
22. Cohen LA, Choi KW, Wang CX, (1988) Influence of dietary fat, caloric restriction, and voluntary exercise on N-nitrosomethylurea-induced mammary tumorigenesis in rats. Cancer Res 48: 4276-4283
23. Courneya KS, Friedenreich CM (1997) Relationship between exercise during treatment and current quality of life among survivors of breast cancer. J Psychosoc Oncol 15: 35-57
24. Craighead PS, Young S (1998) Phase II study assessing the feasibility of using elemental supplements to reduce acute enteritis in patients receiving radical pelvic radiotherapy. Am J Clin Oncol 21(6): 573-578
25. Denmark-Wahnefried W, Peterson B, McBride C, Lipkus I, Clipp E (2000) Current health behaviours and readiness to pursue lifestyle changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 88: 674-684
26. Dicato M, Duhem C, Berchem G, Ries F (2000) Clinical benefit from erythropoietin. Curr Opin Oncol 12(4): 297-302
27. Dorr RT (1999) Managing extravasations of vesicant chemotherapy drugs In: Lipp HR (ed) Anticancer drug toxicity; prevention; management and clinical pharmacokinetic. Dekker, New York, pp 279-318
28. Dorr RT, Holmes BC (1999) Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 26(2 Suppl 7): 108-119
29. Dorr VJ (1998) A practitioner's guide to cancer-related alopecia. Semin Oncl 25: 562-570
30. Dunn SE, Kari FW, French J et al. (1992) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57: 4667-4672
31. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J et al. (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review, Int J Oncol 28(1): 5-23
32. Fakih M, Cao S, Durrani FA, Rustum YM (2005) Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 5(2): 132-135
33. Foster-Nora JA, Siden R (1997) Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm 54(7): 787-800
34. Frakes LA, Brehm TL, Kosty MP et al. (1997) An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20(6): 473-478
35. Gabrilove JL, Jakukowski A, Scher H (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318: 1414-1421
36. Gail MH, Eagan RT, Feld R et al. (1984) Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 54(9): 1802-1813
37. Giannarelli D, Maini CL (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16(1): 86-92
38. Giovannucci E, Rimm EB Ascherio A (1999) Smoking and risk of fatal and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomakers Prev 8: 277-282
39. Grené N, Pointereau-Bellanger A, Conort O et al. (2000) Multicenter study of the impact of prescription guidelines on the use of colony stimulating factors. Anti-Cancer Drugs 11: 109-115
40. Gritz ER (1991) Smoking and smoking cessation in cancer patients. Br J Addict 86: 549-554
41. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3. J Urol 159: 2035-2039
42. Hägglund H,. Ringden O, Öman S et al. (1999) A prospective randomized trial of filgrastim (r-metHuG-GSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 24: 831-836
43. Hansen SW, Groth S, Sorensen PG et al. (1989) Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. Eur J Cancer Clin Oncol 25(4): 733-736
44. Hartmann JT, Fels LM, Franzke A et al. (2000) Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 20(5C): 3767-3773
45. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25(4 Suppl 10): 3-9
46. Heckman KD, Weiner GJ, Davis CS et al. (1997) Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol15(3): 1143-1149
47. Hensley ML, Schuchter LM, Lindley C et al. (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17(10): 3333-3355
48. Hesketh PJ, Kris MG, Grunberg SM et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1): 103-109
49. Hesketh PJ, Crews JR, Cohnen R et al. (1999) Efficancy of a single 1-mg od 2-mg dose of oral granisetron for the prevention of nausea uand vomitino induced by intravenous cyclophosphamide- od Carboplatin-based chemotherapy regimes. Proc ASCO A 18: 2290
50. Hesketh PJ, Grunberg SM, Gralla RJ et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22): 4112-4119
51. Howe HL, Wingo PA, Thun MJ et al. (2001). Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93: 824-842
52. Hsieh LJ, Carter B, Landis PK et al. (2003) Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (Unites States). Urology 61: 297-301
53. Hu H, Jiang C, Ip C et al. (2005) Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11(6): 2379-2388
54. Hughes WT, Armstrong D, Bodey GP et al. (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infekt Dis 25: 551-573
55. Hursting SD, Perkins SN, Phang JM (1994) Caloric restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 91: 7036-7040
56. Husbeck B, Peehl DM, Knox SJ (2005) Redox modulation of human prostate carcinoma cells byselenite increases radiation-induced cell killing. Free Radic Biol Med 38(1): 50-57
57. Johnston-Early A, Cohen MH, Minna JD et al. (1980) Smoking abstinence and small cell lung cancer survival. An association. JAMA 244(19): 2175-2179
58. Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36(6): 766-771
59. Katz A, Epelman S, Anelli A et al. (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121: 128-131
60. Kaushansky K (1998) Thrombopoietin. N Engl J Med 339: 746-754
61. Kern WV, Cometta A, De Bock R et al. (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Eng J Med 341: 312-318
62. Klein HG (1994) Immunologic aspects of blood transfusion. Semin Oncol 21(2 Suppl 3): 16-20
63. Kromhout D, Bloemberg B, Feskens E et al. (2000) Saturated fat, vitamin C and smoking predict long-term population allcause mortality rates in the Seven Countries Study. Int J Epidemiol 29: 260-265
64. Kuderer NM, Lyman GH, Djulbegovic B et al. (2005) Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy: Proc ASCO 23: 8117
65. Kuper H, Boffetta P, Adami HO (2002) Tabacco use and cancer causation: association by tumour type. J Intern Med 252: 206-224
66. Kurbacher CM, Mallmann PK (1998) Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res 18: 2203-2210
67. Lamm DL, Riggs DR, Shriver JS et al. (1994) Mega-dose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151(1): 21-26
68. Lee IM (2003) Physical activity and cancer prevention - data from epidemiologic studies. Med Sci Sports Exerc 35: 1823-1827
69. Lelli G, Montanari M, Gilli G et al. (2003) Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal. J Chemother 15(3): 220-225
70. Lin A, Jabbari S, Worden FP et al. (2005) Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 63(5): 1413-1418
71. Lipp HR, Brokemeyer C (2000) Supportivtherapie in der klinischen Onkologie - Aktueller Stand und Perspektiven. Krankenhauspharmazie 21: 559-575
72. Lipp HP (1999) Dermatological toxicity and hypersensivity reactions associated with the use of cytostatics In: Lipp HP (ed) Anticancer drug toxicity; prevention, management and clinical pharmacokinetics. Dekker, New York, pp 263-275
73. Lopez M, Vici P, Di Lauro K et al. (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16: 86-92
74. Lümmen G, Eisenhardt A, vom Dorp F et al. (2005) Beeinflusst Rauchen das Überleben von Prostatakarzinompatienten? Urologe 44(Suppl): 123
75. MacVicar MG, Winningham ML (1986) Promoting the functional capacity of cancer patients. Cancer Bull 38: 235-239
76. Markman M, Kennedy A, Webster K et al. (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125(7): 427-429
77. Markman M, Kennedy A, Webster K et al.(2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1): 102-105
78. Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26(4): 303-311
79. Micke O, Bruns F, Mucke R et al. (2003) Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 56(1): 40-49
80. Mock V, Dow KH, Meares CJ et al. (1997) Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24(6): 991-1000
81. Morris JD, Pramanik R, Zhang X et al. (2005) Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett 2005
82. Moyad MA (2002) Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 59(4 Suppl 1): 34-40
83. Moyad MA (2003) Bladder cancer prevention, Part I: What do I tell my patients about lifestyle changes and dietary supplements? Curr Opin Urol 13: 363-378
84. Mukherjee P, Sotnikov AV, Mangian HJ et al. (1999) Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 91: 512-523
85. Nakamura K, Kariyazono H, Komokata T et al. (2005) Influence of preoperative administration of omega-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. Nutrition 21(6): 639-649
86. Nordevang E, Callmer E, Marmur A, Holm LE (1992) Dietary intervention in breast cancer patients: effects on food choice. Eur J Clin Nutr 46(6): 387-396
87. Office of Cancer Survivorship. Available athttp://www.de-cups.nci.nih. gov/ocs/prevalance/index.html (accessed October 24,2003)
88. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF (2000) PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85: 481-485
89. Pizzo PA (1984) Granulocytopenia and cancer therapy. Cancer 54: 2649-2656
90. Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11(6): 371-377
91. Rock E, DeMichele A (2003) Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133(11 Suppl 1): 3785-3793
92. Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11): 879-82
93. Scheid C, Hermann K, Kremer G et al. (2004) Randomized, double-blind, controlled study of glycylglutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 20(3): 249-254
94. Schmitz-Dräger BJ, Eichholzer M, Beiche B, Ebert T (2001) Nutrition and Prostate Cancer. Urol Int 67: 1-11
95. Segal R, Evans W, Johnson D et al. (2001) Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19(3): 657-665
96. Shaw L, Bonner H, Schuchter L (1999) Pharmacokinetics of amifostine in cancer patients: The data support non-linear kinetics. Pro Am Soc Clin Oncol A 18: 727
97. Smith MR, Eastham J, Gleason DM et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169(6): 2008-2012
98. Sredni B, Albeck M, Tichler T et al. (1995) Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 13(9): 2342-2353
99. de la Taille A, Hayek OR, Buttyan R et al. (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 84: 845-50
100. Taixiang W, Munro AJ, Guanjian L (2005) Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev 1: CD004540
101. Taper HS, Roberfroid MB (2005) Possible adjuvant cancer therapy by two prebiotics - inulin or oligofructose. In Vivo 19(1): 201-204
102. Tavani A, Bertuccio P, Bosetti C et al. (2005) Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 48: 27-33
103. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7): 665-685
104. Tepler I, Elias L, Smith JW 2nd et al. (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87(9): 3607-3614
105. Teramura M, Kobayashi S, Yoshinaga K et al. (1996) Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 38: 99-102
106. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al. (2000) Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132(5): 364-368
107. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM (2000) Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol 163: 187-190
108. Verdi CJ (1993) Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 9(3): 185-195
109. Webb IJ, Anderson KC (1999) Risks, costs, and alternatives to platelet transfusions. Leuk Lymphoma 34(1-2): 71-84
110. Weijl NI, Elsendoorn TJ, Lentjes EG et al. (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40(11): 1713-1723
111. Weiss JF, Landauer MR (2003) Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189(1-2): 1-20
112. Wilkes JD (1998) Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 25(5): 538-551
113. Winningham ML, MacVicar MG (1998) The effect of aerobic exercise on patient reports of nausea. Oncol Nurs Forum 15: 447-450
114. Wiseman LR, Spencer CM (1998) Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56(3): 385-403